Prior research by our group showed improved survival and attenuation of hyperinflammatory tissue injury in mice with disseminated candidiasis receiving a CXCR1/CCL3 inhibitor during the initial inflammatory stage (105); however, combined application with ICIs during fungal infections remains to be studied. This evidence concerns the gene CXCR1 and fungal infectious disease.